Abdera Therapeutics
Lori Lyons-Williams is an accomplished executive in the biotech and pharmaceutical sectors, currently serving as President and CEO of Abdera Therapeutics since May 2022. In addition to this role, Lori has been an Independent Director at RAPT Therapeutics and Contineum Therapeutics since November 2021 and September 2020, respectively. Previous leadership experience includes Chief Executive Officer of a stealth biotech company and President and Chief Operating Officer at Neumora. Lori played a significant role as Chief Commercial Officer at Dermira and held various senior positions at Allergan, where responsibilities encompassed sales, marketing, and management in the urology and dermatology divisions. The educational background includes an MBA in Marketing and International Business from the University of Minnesota and a BA in Pre-Med from Virginia Tech.
This person is not in any offices
Abdera Therapeutics
1 followers
Abdera is an oncology company developing targeted alpha therapies (TATs) for patients with relapsed, refractory, and metastatic cancers. Its targeted radiotherapies utilize purpose-built vectors to specifically target high-energy radio-isotopes to tumors and metastatic cancer lesions. This new class of drugs holds tremendous untapped therapeuticand commercial potential, and has generated over $10B in recent M&A, financings, and product launches – and are expected to comprise 70% of the $30B nuclear medicine market by 2030.It was launched by adMare BioInnovations, Canada’s global life sciences venture, in partnership with industry leaders AbCellera, and some of the country’s most successful scientist entrepreneurs.